Alzheimer Disease: Targacept's Failed TC-1734 Phase 2b Trial
From a Targacept press release:
Targacept Phase 2b Clinical Trial in Alzheimer’s Disease Does Not Show Superiority of TC-1734 Over Donepezil
July 14, 2014
"Winston-Salem, NC – Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced top-line results from a Phase 2b monotherapy clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer’s disease. In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer’s disease, after 52 weeks of treatment. The trial did not include a placebo arm and was not designed to determine whether TC-1734 is equivalent to donepezil. The co-primary endpoints for the study were measures of cognitive function and global function. Consistent with previous clinical results, TC-1734 exhibited a benign safety and tolerability profile."
Read the full press release from Targacept
- Alzheimer: Clinical Trials Day At The Aaic2015 Conference
Alzheimer's Association Press Release at 0700 hrs EDT on 22 July 2015. - Longer-Term Analysis of Phase 3 Solanezumab (Lilly) Up to 3.5 Years - Biomarker Results from Phase 3 Gantenerumab (Roche) Trial - New Data from Aducanumab (Biogen) Phase 1b...
- Alzheimer's Disease: Negative Bapineuzumab Findings In Phase Iii Trial
Critical reading for those interested in Alzheimer's clinical trials: first results from the BAP Phase III program. The link includes additional links to a New York Times article and a company press release. From FierceBiotech: UPDATED: Pfizer, J&J...
- Tc-5214 Depression Phase Iii Results
From Fierce Biotech: Key AZ/Targacept depression drug flunks first Phase III test By John Carroll November 8, 2011 — 6:49am ET [snippet] "The high-profile depression drug TC-5214 has failed the first in a string of Phase III studies, dealing AstraZeneca's...
- Acadia's Pimavanserin And Parkinson Disease Psychosis
FierceBiotech reported today about a failed Phase III trial of Acadia's Pimavanserin in a study of Parkinson's Disease Psychosis (sometimes abbreviated as "PDP"): ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in...
- Business World: Neurochem's Alzhemed And Alzheimer Disease
Neurochem completes patient recruitment for North American Phase III clinical trial for Alzhemed(TM) Milestone on Schedule Tuesday July 5, 8:31 am ET LAVAL, QC, July 5 /PRNewswire-FirstCall/ - Neurochem Inc. ... announced today the completion of recruitment...